title: Comparison of the analgesic efficacy of oral ABT-116 administration with that of transmucosal buprenorphine administration in dogs.
abstract: OBJECTIVE
  To evaluate the analgesic efficacy of ABT-116, a transient receptor potential cation channel vanilloid subfamily V member 1 antagonist, and compare it with that of buprenorphine by measurement of mechanical and thermal nociceptive thresholds in dogs.
  
  
  METHODS
  Six 7- to 8-month-old dogs (3 males and 3 females).
  
  
  METHODS
  In a crossover study design, all dogs received ABT-116 (30 mg/kg, PO) and buprenorphine (0.03 mg/kg, orotransmucosally), with each treatment separated by 1 week. Physiologic variables were recorded prior to and 1, 6, and 24 hours after drug administration. Thermal (thoracic) and mechanical (dorsolateral aspect of the radius [proximal] and dorsopalmar aspect of the forefoot [distal]) nociceptive thresholds were assessed prior to (baseline) and 15 minutes and 1, 2, 4, 6, 12, 18, and 24 hours after treatment.
  
  
  RESULTS
  Buprenorphine administration resulted in higher overall thermal and proximal mechanical nociceptive thresholds, compared with ABT-116. Distal mechanical nociceptive thresholds after treatment were higher than baseline values for both treatments, but the magnitude of change was greater for buprenorphine at 1 hour after administration. Whereas HR and RR sporadically differed from baseline values after ABT-116 administration, rectal temperature increased from a baseline value of 39 ± 0.2°C (mean ± SD) to a peak of 40.6 ± 0.2°C at 6 hours.
  
  
  CONCLUSIONS
  In dogs without inflammation or nerve injury, PO administration of ABT-116 did not consistently result in an increase in nociceptive thresholds. However, clinically relevant increases in rectal temperature were identified after ABT-116 administration.
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523, USA.
authors.forename: Sirirat
authors.initials: S
authors.lastname: Niyom
authors.forename: Khursheed R
authors.initials: KR
authors.lastname: Mama
authors.forename: Marlis L
authors.initials: ML
authors.lastname: De Rezende
mesh_terms: D058956:Administration, Mucosal; D000701:Analgesics, Opioid / Q000494:pharmacology*; D000818:Animals; D002047:Buprenorphine / Q000008:administration & dosage / Q000494:pharmacology*; D018592:Cross-Over Studies; D004285:Dogs; D005260:Female; D007191:Indazoles / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D010146:Pain / Q000188:drug therapy / Q000662:veterinary; D010147:Pain Measurement / Q000662:veterinary*; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology*; D050916:TRPV Cation Channels / Q000037:antagonists & inhibitors
chemical_list: C551310:ABT 116; D000701:Analgesics, Opioid; D007191:Indazoles; D010671:Phenylurea Compounds; D050916:TRPV Cation Channels; D002047:Buprenorphine